Mekinist trametinib: Interim Phase I/II data

Interim data from 36 mCRC patients with V600 BRAF mutations in an open-label, U.S. and Australian Phase I/II trial showed that twice-daily 150 mg Tafinlar dabrafenib plus once-daily 2 mg Mekinist led to 1 complete response, 3 partial responses and 18 cases of stable disease. Median PFS was 3.5 months. The most frequent adverse events included pyrexia, nausea, fatigue, chills, vomiting, headache, peripheral edema, anemia and decreased appetite. There were 2 discontinuations due to adverse events. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...